Crossref

1. Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial

- Mostafa Yakoot

- Alaa M. Abdo

- Siham Abdel-Rehim

- Sherine Helmy

2. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial

- Shahin Merat

- Shahin Merat

- Amir-Houshang Sharifi

- Hossein Poustchi

- Eskandar Hajiani

- Abdolsamad Gharavi

- Jalal Karimi

- Fariborz Mansour-Ghanaei

- Mohammad-Reza Fattahi

- Lida Ahmadi

- Mohammad-Hossein Somi

- Hamid Kalantari

- Mohammad-Reza Ghadir

- Farshad Sheikhesmaeili

- Nadieh Baniasadi

- Masoudreza Sohrabi

- Seyedhamid Moosavy

- Masood Ziaee

- Mohammad-Javad Zahedi

- Marjan Mokhtare

- Shahnaz Sali

- Babak Sayad

- Behrooz Afshar

- Alireza Bakhshipour

- Abazar Parsi

- Afsaneh Sharifian

- Taghi Amiriani

- Zeinab Malekzadeh

- Dorsa Merat

- Azita Ganji

- Fereidoun Rahmani-Samani

- Raika Jamali

- Masoomeh Sofian

- Mohammad Ghezlou

- Amir Ali Sohrabpour

- Ladan Goshayeshi

- Seyed-Mohammad Valizadeh-Toosi

- Layli Eslami

- Iradj Maleki

- Ahmad Hormati

- Ali-Akbar Shayesteh

- Elahe Shayesteh

- Alireza Norouzi

- Zahra Abna

- Alireza Janbakhsh

- Hafez Fakheri

- Mohammad Minakari

- Hossein Sardarian

- Adel Fallah Ghajary

- Mojtaba Fattahi-Abdizadeh

- Maryam Latifnia

- Fatemeh Roozbeh

- Shahram Agah

- Saba Fakhrieh-Asl

- Alireza Nateghi-Baygi

- Babak Fattahi

- Helia Nateghi-Baygi

- Andrew Hill

- Reza Malekzadeh

3. Pure component contribution (PCCA) and synergy interval partial least squares (siPLS) algorithms for efficient resolution and quantification of overlapped signals; an application to novel antiviral tablets of daclatasvir, sofosbuvir and ribavirin

- Maha Mahmoud Abou El-Alamin

- Maha Abd Elrahman Sultan

- Maha Hegazy

- Alastair William Wark

- Marwa Mohamed Azab

4. Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis

- Mohammad Saeid Rezaee-Zavareh

- Khashayar Hesamizadeh

- Bita Behnava

- Seyed Moayed Alavian

- Mohammad Gholami-Fesharaki

- Heidar Sharafi

5. Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-Analysis

- Mohammad Saeid Rezaee-Zavareh

- Khashayar Hesamizadeh

- Heidar Sharafi

- Seyed Moayed Alavian

6. Research progress on the direct antiviral drugs for hepatitis C virus

- Jianjun Gao

- Chuanxia Ju

7. Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C−infected patients with thalassemia

- Arezoo Khosravi

- Hamidreza Karimi‐Sari

- Mahdi Abedi‐Andani

- Bita Behnava

- Ali Namvar

- Ali Anvar

- Seyed Moayed Alavian

8. Letter: the efficacy of interferon‐free regimens in HCV‐related Child C cirrhosis needs careful interpretation

- M. S. Rezaee‐Zavareh

- S. M. Alavian

9. Comment on ‘Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study’

- Seyed M. Alavian

- Heidar Sharafi

10. Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017

- Seyed Moayed Alavian

- Heidar Sharafi

11. The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3

- Shahin Merat

- Amir Houshang Sharifi

- Arghavan Haj-Sheykholeslami

- Hossein Poustchi

- Babak Fattahi

- Alireza Nateghi-Baygi

- Seyed Moayed Alavian

- Reza Malekzadeh